2 outstanding ASX 200 shares to buy this month according to analysts

Here are a couple of ASX 200 shares that have been rated as buys…

| More on:
a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are a lot of options for investors to choose from on the ASX 200. Two that could be in the buy zone right now are listed below.

Here's why analysts rate them as buys:

Aristocrat Leisure Limited (ASX: ALL)

The first ASX 200 share to look at is Aristocrat Leisure. It is one of the world's leading gaming technology companies responsible for many of the most popular pokie machines globally. In addition to this, the company has a growing digital business with a portfolio of hugely popular mobile games such as RAID: Shadow Legends. It is also in the process of acquiring UK listed real money gaming business Playtech for $3.9 billion.

Morgans is a fan of the company and currently has an add rating and $52.00 price target on its shares.

It commented: "We reiterate our ADD rating. In our opinion, the acquisition of PTEC gives ALL the opportunity to get to scale quickly in a market segment forecast to grow at a double-digit rate over the next five years. We expect the strong sector growth to be driven by a North America market growing at a CAGR of close to 50% as more US states liberalise and allow online iGaming and online sports betting."

CSL Limited (ASX: CSL)

Another ASX 200 share that could be in the buy zone is CSL. It is one of the world's leading biotechnology companies, comprising the CSL Behring and Seqirus businesses. Both are leaders in their respective fields – plasma therapies and vaccines.

Citi is bullish on the company, particularly following its Vifor Pharma acquisition announcement, and appears to see the weakness in the CSL share price as a buying opportunity for investors. It has a buy rating and $340.00 price target on its shares.

Citi said: "CSL has announced that the acquisition of Vifor Pharma – it is acquiring the company at CHF165.5 (US$179.25), a ~65% premium to where the stock was trading pre bid discussion and a ~37% premium to the three-month VWAP. We calculate the acquisition to be ~9% accretive to NPATA per share (NPAT before acquisition-related amortization) – a proxy for cash flow."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

Excited couple celebrating success while looking at smartphone.
Blue Chip Shares

3 no-brainer ASX 200 shares to buy with $5,000

You don't need a brain to see that these shares could be quality investments.

Read more »

Three young people lie in the surf on a beach wearing santa hats.
Blue Chip Shares

BHP, Macquarie, and Westpac: Naughty or nice? 3 popular ASX shares examined

Let's see if these blue chips made their shareholders smile in 2025.

Read more »

Two men laughing while bouncing on bouncy balls
Blue Chip Shares

I think these ASX blue chips shares are primed for a major rebound in 2026

2025 was not kind to these shares. Here's why things could be better next year.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Blue Chip Shares

Is now the time to buy Pro Medicus shares?

After a 13% pullback, Pro Medicus shares are back in focus. Is this weakness an opportunity?

Read more »

Two strong women battle it out in the boxing ring.
Investing Strategies

Why these 2 battered ASX 200 stocks could shine in 2026

Bruised this year, but analysts see the heavyweight shares bounce back in 2026.

Read more »

A smiling woman holds a Facebook like sign above her head.
Blue Chip Shares

CSL and more blue-chip ASX 200 bargains I'd buy before 2026

Here's why I think these shares could be cheap buys before the end of the year.

Read more »

A happy couple drinking red wine in a vineyard.
Blue Chip Shares

What can investors expect from Treasury Wines' update tomorrow?

Tomorrow’s announcement is shaping up to be one of the most consequential updates in years for Treasury Wine Estates.

Read more »

man in old fashioned suit and hat looking through magnifying glass
Blue Chip Shares

Is the CSL share price a generational bargain at $180?

CSL shares are currently trading near a 7-year low.

Read more »